Lu Xiao, Xu Shanxiang
Department of Emergency Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Medicine (Baltimore). 2020 May 22;99(21):e20393. doi: 10.1097/MD.0000000000020393.
Several intensive-care units (ICUs) in Wuhan are nonstandard wards that were repurposed from general wards. Considering the shortage of medical resources and the need to prevent nosocomic infection, the respiratory-treatment strategy in these nonstandard ICUs is different from those in general wards and standard ICUs. High-flow nasal cannula (HFNC) plays an important role in nonstandard ICUs and is beneficial to the patients therein.
In this study, we analyzed four cases of HFNC-treated patients with severe coronavirus disease 2019 (COVID-19) in a makeshift ICU and summarized our experience.
Four patients diagnosed with COVID-19 according to World Health Organization (WHO) interim guidance were admitted to the makeshift ICU.
All patients had oxygen treatment with HFNC, as well as regular treatment of antivirals and traditional Chinese medicine.
Two patients survived after treatment, while the other two died from acute respiratory distress syndrome (ARDS) and heart failure, respectively.
Patients with severe and critical COVID-19 often have poor prognoses after mechanical ventilation, exhibiting corresponding complications such as ventilator-associated pneumonia and deep-vein thrombosis, which significantly prolongs length of stay in the ICU. HFNC could prevent intubation in some patients, thereby avoiding the above complications; however, this needs confirmation in further clinical studies. This treatment reduced difficulty and workloads for healthcare professionals, had good tolerability for patients, might not significantly increase the risk of infection for healthcare professionals, and do not require additional preventive measures against nosocomic infection. HFNC treatment has its advantages in providing oxygen therapy in COVID-19, but healthcare professionals should still pay close attention to changes in patients' oxygenation rates and respiratory frequency.
武汉的几家重症监护病房(ICU)是由普通病房改造而来的非标准病房。考虑到医疗资源短缺以及预防医院感染的需要,这些非标准ICU的呼吸治疗策略与普通病房和标准ICU不同。高流量鼻导管(HFNC)在非标准ICU中发挥着重要作用,对其中的患者有益。
在本研究中,我们分析了一家临时ICU中4例接受HFNC治疗的新型冠状病毒肺炎(COVID-19)重症患者,并总结了经验。
根据世界卫生组织(WHO)临时指南确诊为COVID-19的4例患者被收治入临时ICU。
所有患者均接受了HFNC氧疗,以及抗病毒药物和中药的常规治疗。
2例患者治疗后存活,另外2例分别死于急性呼吸窘迫综合征(ARDS)和心力衰竭。
重症和危重症COVID-19患者机械通气后预后往往较差,会出现呼吸机相关性肺炎和深静脉血栓形成等相应并发症,这显著延长了ICU住院时间。HFNC可在部分患者中避免插管,从而避免上述并发症;然而,这需要进一步的临床研究予以证实。这种治疗减轻了医护人员的难度和工作量,患者耐受性良好,可能不会显著增加医护人员的感染风险,且不需要额外的医院感染预防措施。HFNC治疗在COVID-19氧疗方面具有优势,但医护人员仍应密切关注患者氧合率和呼吸频率的变化。